Global

News Release Archive

This section features CSL Behring news releases that are more than 18 months old. Click the tabs to select releases in your area of interest. Click Resources to find additional background material on CSL Behring.

All Releases
Corporate
Immunology
Bleeding Disorders
Hereditary Angioedema (HAE)
Pulmonary
Fluid Management
Resources

All Releases

14 November 2007 Study Shows Need to Test Greater Number of COPD and Asthma Patients for Underdiagnosed Pulmonary Disease

A new study finds that a higher than expected number of COPD and severe asthma patients had abnormal low levels of alpha-1 antitrypsin (AAT), suggesting that need for broader criteria for AAT deficiency testing. AAT deficiency, also known as Alpha-1, is a widely undiagnosed hereditary disorder that is usually fatal in its severe form.

> Read More
09 November 2007 L-Proline Stabilizer Used in the Intravenous Immunoglobulin Product Privigen® Shows No Neurological Side Effects Compared with Currently Used Stabilizers

CSL Behring announced new data today that demonstrates that L-proline causes no neurological effects, including convulsive behaviour and spatial learning and memory, even at high doses, when compared with glycine, which is used in many current intravenous immunoglobulin (IVIg) products. L-proline is used as stabilizer in the new Immune Globulin Intravenous (human) 10% product (Privigen®). The data were presented at the American Congress of Allergy, Asthma and Immunology (ACAAI) in Dallas, Texas.

> Read More
09 November 2007 New Hope in Immunodeficiency Treatment for Improved Tolerability and Convenience in the use of Immune Globulin Intravenous (Human) 10% Liquid (Privigen®)

CSL Behring today announced data on the use of L-proline as a new single stabilizer for Immune Globulin Intravenous (Human) 10% Liquid (Privigenâ). Researchers found that the use of L-proline, a naturally occurring amino-acid, inhibited dimer formation more efficiently when compared with other additives like glycine, used as a stabilizer in conventional immunoglobulin products. In addition, the formulation with L-proline was found to prevent aggregation. The data were presented today at the American Congress of Allergy, Asthma and Immunology (ACAAI) in Dallas, Texas.

> Read More
12 October 2007 CSL Behring Completes Enrollment of Phase III Clinical Study of C1 Inhibitor in Treating Hereditary Angioedema

CSL Behring announced today that it has completed patient enrollment of a Phase III clinical trial of human pasteurized C1-inhibitor (C1-INH) concentrate to treat patients with hereditary angioedema (HAE).

> Read More
01 August 2007 CSL to Build High-Speed Syringe Fill Line at its Kankakee (Il) Facility

CSL Behring today announced plans to invest $15 million to expand its manufacturing facility here by adding a high-speed, single-dose syringe filling line. Plans call for the line to be operational in 2010, when the company intends to contract with its sister company, CSL Biotherapies, to provide filling and packaging services for seasonal influenza vaccine.

> Read More
Page 51 of 53 First | Previous | Next | Last

Share
LinkedIn Twitter Facebook Google+